Literature DB >> 12458024

Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19.

F Lakehal1, C J Wurden, T F Kalhorn, R H Levy.   

Abstract

Multiple studies suggest that phenytoin concentrations increase with CBZ co-medication. This study evaluated the hypothesis that CBZ and/or its major metabolite (CBZE) inhibit CYP2C19-mediated phenytoin metabolism using human liver microsomes and cDNA-expressed CYP2C19. Oxcarbazepine (OXC), and its 10-monohydroxy metabolite (MHD) were also evaluated. CBZ and MHD inhibited CYP2C19-mediated phenytoin metabolism at therapeutic concentrations. Thus, administration of CBZ and OXC with CYP2C19 substrates with narrow therapeutic ranges should be done cautiously.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12458024     DOI： 10.1016/s0920-1211(02)00188-2

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN： 0920-1211            Impact factor:   3.045


  6 in total

1.  Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: results from a phase I, randomized, crossover trial.

Authors:  Willi Cawello; Christa Mueller-Voessing; Andreas Fichtner
Journal:  Clin Drug Investig       Date:  2014-05       Impact factor: 2.859

2.  Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.

Authors:  C K Yeung; Y Fujioka; H Hachad; R H Levy; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2010-12-01       Impact factor: 6.875

3.  Inhibitory effects of wogonin on catalytic activity of cytochrome P450 enzyme in human liver microsomes.

Authors:  Tingting Li; Ning Li; Qinglong Guo; Hui Ji; Di Zhao; Shan Xie; Xiaonan Li; Zhixia Qiu; Deen Han; Xijing Chen; Qidong You
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-06-29       Impact factor: 2.441

4.  Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.

Authors:  Anita Rakic Ignjatovic; Branislava Miljkovic; Dejan Todorovic; Ivana Timotijevic; Milena Pokrajac
Journal:  Br J Clin Pharmacol       Date:  2008-12-05       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of oxcarbazepine.

Authors:  Theodor W May; Elisabeth Korn-Merker; Bernhard Rambeck
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.